Table 1.

Characteristics of RCTs evaluated PDGF safety and effectiveness.

Ref	Study	Intervention	Type of control	Size and the old of the wound	# of patients	Antibiotics application during the treatment period (if needed)	Baseline HbA1C	Types of wound and grade of wound	Dressing type	Offloading	Treatment duration	Follow up period posttherapy
[8]	Phase III RCT	Becaplermin® gel (Regranex) 100 and 30 μg/g vehicle gel once daily	Placebo	>2cm2 for a period of at least 8 weeks	382	Y	6.5-7.2	Stage III or IV (IAET guide)	Moist saline-soaked gauze dressings	Y	20 weeks	3 months
[9]	RCT	30 μg PDGF per g of gel once a day	Placebo	1-100 cm2 at least 8-week duration	118	N	NM	NM	Non adherent saline soaked gauze	Y	20 weeks	NM
[10]	RCT	PDGF gel once daily	Placebo hydrogel	1-16 cm2	46	N	Y	Wagner grade I	Saline moistened gauze and nonadherent wound dressing	Y	4 months	6 months
[11]	RCT	0.01% rhPDGF-BB gel once a day	Standard wound care	14.6 ± 13.2 at least 4-week duration	20	N	8.05 ± 0.84	Wagner's grade II	Moist saline and casting	Y	20 weeks	NM
[12]	RCT	PDGF gel 7 μg/cm2 of ulcer per day	Two active controls: antiseptics and hyperbaric oxygen therapy	8-week duration	60	Y	NM	Equals to Wagner grade II, III	Saline moistened gauze	NM	10 weeks	NM
[13]	RCT	rhPDGF gel 0.01%	Active: KY Jelly (Ethnor)	26-30 cm2 at least 4-week duration	50	Y	NM	IAET stage III and IV	Moist dressing	Y	10 weeks	NM
[14]	RCT (phase III)	0.01% PDGF gel containing 100 μg/g	Placebo	1-40 cm2 at least 4 weeks	111	Y	<12%		Moist saline gauze	Y	20 weeks	NM
[15]	RCT	Regranex (PDGF) 0.01% plus TheraGuaze	Active (TheraGuaze)	1-8 cm2	32	NM	<10%	Wagner grade I/II	TheraGuaze	Y	NM	Study period: 20 weeks

PDGF: platelet-derived growth factor; Y: yes; N: no; NM: not mentioned; IAET: International Association of Enterostomal Therapy.